Jonathan
Schisler

The Schisler Lab has made significant strides in neurodegeneration research, notably being the first to connect the loss of the CHIP/STUB1 protein to human neurodegenerative diseases. This pioneering discovery established a critical link between protein quality control and brain health, revealing how the absence of CHIP contributes to neuronal damage. Building on this foundation, the lab is now exploring how CHIP could be utilized as a therapy for Alzheimer’s disease (AD). Their current efforts focus on preclinical testing of improved versions of CHIP to prevent the aggregation of tau proteins—a hallmark of AD that leads to brain cell damage and memory loss. By employing advanced molecular and genetic techniques, the Schisler Lab aims to develop CHIP-based interventions that could reduce tau pathology, protect neurons, and ultimately enhance cognitive outcomes for AD patients, offering a promising new direction for treatment.